ACLX Arcellx, Inc.

8-K Current Report

Filed: February 23, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Arcellx, Inc. (ACLX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Gilead Sciences acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, totaling up to $120.00/share
• CVR pays $5.00 only if anito-cel cumulative worldwide sales exceed $6.0B by December 31, 2029 — milestone is high-bar, payment not guaranteed

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Arcellx merger agreement announced Feb 23, 2026 alongside FDA acceptance of BLA for anito-cel
• Anito-cel targets BCMA for relapsed/refractory multiple myeloma — BLA acceptance signals regulatory review underway

+1 more insights

Get deeper insights on Arcellx, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.